10 Dec 2009 07:00
10 December 2009
Immunodiagnostic Systems Holdings PLC
Exercise of Share Options and Directors' Dealings
Immunodiagnostic Systems Holdings PLC ("the Company"), a leading producer of diagnostic testing kits, announces that on 9 December 2009, certain Directors exercised options over in aggregate 1,134,297 ordinary shares of 2p each in the Company ("Ordinary Shares") and subsequently placed 505,628 ordinary shares in aggregate with a number of institutional investors. Notification was received by the Company yesterday. Application will be made at the earliest practicable opportunity for admission of the new ordinary shares to trading on AIM.
| Director | Exercise Price | Number of Shares | |
| Approved | Unapproved | ||
| Roger Duggan | 51p | 196,078 | 137,539 |
| Paul Hailes | 51p | 196,078 | 137,539 |
| Anthony Wilks | 51p | 0 | 133,446 |
| David Evans | 51p | 0 | 333,617 |
The options were exercised under the Company's Approved Share Option Scheme and the Unapproved Share Option Scheme, save for David Evans' which were exercised under a separate Share Option Agreement.
Directors' Dealings
Following the exercise of Share Options the Directors disposed of a number of their shares. Following these disposals they are interested in the following shares:
| Director | Sale Price | Disposal of Shares | Total Holding following notification | |
| Number | % of issued Share Capital | |||
| Roger Duggan | 605p | 80,357 | 2,476,187 | 8.97% |
| Paul Hailes | 605p | 137,539 | 1,112,728 | 4.03% |
| Anthony Wilks | 605p | 133,446 | 58,820 | 0.21% |
| David Evans | 605p | 154,286 | 522,458 | 1.89% |
| Alain Rousseau | 605p | 35,000 | 50,584 | 0.18% |
Total Voting Rights
In accordance with FSA's Disclosure and Transparency Rules, the Company advises that its increased issued share capital comprises 27,615,110 ordinary shares of 2 pence each. The voting rights of all of these shares are identical with each share carrying the right to one vote. The Company holds no ordinary shares in Treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Immunodiagnostic Systems Holdings PLC under the Disclosure and Transparency Rules.
Contacts:
| Immunodiagnostic Systems Holdings PLC | Tel: 0191 519 0660 |
| Roger Duggan, CEO | |
| Paul Hailes, Finance Director | |
| Brewin Dolphin Investment Banking | Tel: 0845 213 4730 |
| Andrew Emmott Sean Wyndham-Quin | |
| Walbrook PR Ltd | Tel: 020 7933 8787 |
| Paul McManus | Mob: 07980 541 893 |